Larazotide Acetate: A Tight-Junction-Regulating Octapeptide for Intestinal Barrier Research

Research summary. Larazotide acetate (INN-202; AT-1001) is a synthetic octapeptide designed to regulate intestinal tight junctions and reduce pathological epithelial permeability. It was derived from the N-terminal region of human fetal zonulin and is best known as the most clinically advanced peptide candidate for celiac disease, where it has been studied as an oral, gut-restricted adjunct to a gluten-free diet. Beyond celiac disease, it has attracted research interest in other intestinal barrier-injury models including ischaemia/reperfusion and collagen-induced arthritis.

Molecular profile

• Sequence: Gly-Gly-Val-Leu-Val-Gln-Pro-Gly (GGVLVQPG)
• Class: Single-chain octapeptide; tight-junction regulatory peptide
• Other designations: AT-1001, INN-202, larazotide
• Origin rationale: Designed from the N-terminal region of human fetal zonulin and structurally related to the receptor-binding motif shared with the Vibrio cholerae zonula occludens toxin pathway
• Formulation: Oral, delayed-release; designed for gut-restricted (non-systemic) action

Mechanism of action

Larazotide acts at the apical surface of the intestinal epithelium and is proposed to operate through several converging tight-junction-stabilising effects:

• Zonulin-pathway antagonism. Zonulin is a permeability modulator released in response to luminal gliadin and certain enteric microbes; it signals through PAR2- and EGFR-associated pathways to disassemble tight junctions. Larazotide is proposed to competitively inhibit zonulin signalling and prevent gliadin-induced tight-junction opening.
• Stabilisation of tight-junction architecture. Reduced rearrangement and redistribution of ZO-1, occludin, and the actin cytoskeleton in epithelial models exposed to barrier-disruptive challenges.
• Modulation of myosin light chain (MLC) phosphorylation. Phosphorylated MLC drives contractile tension in the perijunctional actomyosin ring that pulls tight junctions open; larazotide attenuates injury-associated MLC phosphorylation, supporting membrane retention of occludin.
• Active in the apical compartment only. The peptide is designed to act locally at the luminal face of the epithelium, with minimal systemic absorption.

The precision of acting locally rather than systemically is a defining feature: larazotide is conceptually a barrier-repair drug rather than an immunosuppressant or systemic anti-inflammatory.

Preclinical and clinical research highlights

Celiac disease — adult clinical studies. Larazotide has been the subject of phase 2 studies in adult celiac patients on a gluten-free diet who continued to experience symptoms attributable to inadvertent gluten exposure. A multicentre trial (Leffler et al., 2012) reported that larazotide attenuated gliadin-induced increases in intestinal permeability and reduced symptom scores at the lower doses tested [1]. The compound subsequently advanced into phase 3 development.

Tight-junction and zonulin-pathway studies. In epithelial cell-culture models, larazotide reduces gliadin- or zonulin-induced redistribution of ZO-1 and actin and preserves transepithelial electrical resistance (TEER).

Collagen-induced arthritis model. In rodent models, larazotide prevented zonulin-associated increases in intestinal macromolecular flux and supported tight-junction protein expression in the pre-arthritic phase, supporting a model in which intestinal barrier integrity contributes to systemic inflammatory disease initiation.

Ischaemia/reperfusion injury. In a porcine intestinal I/R injury model, larazotide enhanced ex vivo barrier recovery, increasing TEER and decreasing macromolecular flux during the recovery phase.

Pharmacokinetics and regional delivery. Porcine studies of orally administered delayed-release larazotide show detection throughout the small intestine, with peak concentrations in the duodenum and proximal jejunum approximately one hour after dosing.

Dose–response complexity

A notable pharmacological feature reported across larazotide studies is that higher doses do not necessarily produce stronger effects, and in some injury models actually attenuate barrier recovery. The proposed mechanism is brush-border enzymatic fragmentation of the parent octapeptide into inhibitory fragments that interfere with intact-peptide activity. This has substantial implications for formulation design: release timing, regional delivery, and exposure of intact peptide to brush-border peptidases all influence the apparent dose–response curve.

Analogue development

To address fragmentation-related dose limitations, all-D-amino acid analogues such as A6 have been developed. In a porcine injury model, A6 produced efficacy at lower doses than the parent peptide and showed slower brush-border degradation. Micro-dosing and delayed-release strategies have also been explored as ways to limit inhibitory-fragment formation while preserving the desired barrier-protection profile.

Current research status

Larazotide acetate is an investigational research peptide that has reached late-stage clinical development for celiac disease as an adjunct to a gluten-free diet. It is not currently approved as a therapeutic by major regulatory authorities. Active research domains include:

• Celiac disease — late-stage clinical investigation
• Non-celiac gluten sensitivity and other gluten-related barrier-permeability disorders
• Inflammatory bowel disease and intestinal barrier-injury models
• Intestinal ischaemia/reperfusion and post-surgical recovery research
• Mechanistic studies of zonulin–PAR2/EGFR signalling and the perijunctional actomyosin ring
• Analogue and formulation development to address brush-border fragmentation

Key takeaways for researchers

• Larazotide acetate is a gut-restricted octapeptide designed to stabilise intestinal tight junctions through zonulin-pathway antagonism and reduction of MLC phosphorylation.
• It is the most clinically advanced peptide candidate in celiac disease, with reported reductions in gliadin-induced permeability and symptom scores in phase 2 trials.
• Its non-systemic design distinguishes it from many peptide therapeutics that rely on systemic distribution.
• Brush-border enzymatic fragmentation produces a non-monotonic dose–response curve that complicates dose selection and motivates analogue development (A6).

References

1. Leffler DA, Kelly CP, Abdallah HZ, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. American Journal of Gastroenterology. 2012;107(10):1554–1562.

---

This article is provided for educational and research purposes only. Larazotide acetate is an investigational peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.